Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 2/20 | 0.53 |
| ▸ | CCNK | O75909 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CCND3 | P30281 | 1/20 | 0.53 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.52 |
| ▸ | WEE1 | P30291 | 5/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.52 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374403 | 0.85 | ALK (0.56) | CDK9CCNKCCNA2CDK2CCND3 | |
| SCHEMBL20816283 | 0.84 | MAPT (0.54) | CDK9CCNKCCNA2CDK2CCND3 | |
| SCHEMBL374559 | 0.82 | WEE1 (0.48) | CDK9CCNA2CDK2CCND3WEE1 | |
| SCHEMBL19409829 | 0.80 | RAD52 (0.62) | CDK9CCNKCCNA2CDK2CCND3 | |
| SCHEMBL374708 | 0.80 | HCK (0.58) | KDM1AADRA2AADRA2BADRA2CWEE1 | |
| SCHEMBL17466591 | 0.77 | CDK9 (0.59) | CDK9CCNKCCNA2CDK2CCND3 | |
| SCHEMBL2377742 | 0.77 | RAD52 (0.62) | KDM1AADRA2AADRA2BADRA2CRAD52 | |
| SCHEMBL4948699 | 0.77 | WEE1 (0.65) | CDK9CCNKCCNA2CDK2CCND3 | |
| SCHEMBL29371810 | 0.77 | KDM1A (0.62) | CDK9CCNKCCNA2CDK2CCND3 | |
| SCHEMBL28202825 | 0.76 | KDM1A (0.56) | CDK9CCNKCCNA2CDK2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624897-B2 | Chlorobenzene substituted azaaryl compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-04-21 | — | — | US | disclosed |
| US-20190083499-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2019-03-21 | — | — | US | disclosed |
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-2409969-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | disclosed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2409969-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| EP-1761505-B1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| CN-101035769-A | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2007-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | CDK9 151/4885CCNK 221/4885CCNA2 484/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | CDK9 151/4885CCNK 221/4885CCNA2 484/4885 |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | CDK9 151/4885CCNK 221/4885CCNA2 484/4885 |
| US-10624897-B2 | Chlorobenzene substituted azaaryl compounds | MKI67, CTCF, CDKN1A | CDK9 184/4885CCNK 325/4885CCNA2 53/4885 |
| US-20190083499-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | MKI67, CTCF, CDKN1A | CDK9 184/4885CCNK 325/4885CCNA2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.